Stuart Schnitt about the role of Artificial Intelligence in Pathology – Dana-Farber’s Breast Oncology Center
Paolo Tarantino shared a post by Dana-Farber’s Breast Oncology Center on X/Twitter: .
“AI won’t replace pathologists.
But pathologists that use AI may replace those that don’t use it.”
Quoting Dana-Farber’s Breast Oncology Center’s post:
“Stuart Schnitt, MD discussed the role of Artificial Intelligence in Pathology in the special lecture on the future of pathology in Breast Cancer at the Harvard Breast Cancer Course.”
Source: Paolo Tarantino/X and Dana-Farber’s Breast Oncology Center/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023